Association of a functional polymorphism (Gln261Arg) in 12-lipoxygenase with breast cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 317-323

  Prasad, Vidudala V T S ^a   Kolli, Padma ^a   Moganti, Divya ^a  

^a Indo American Cancer Institute and Research Centre   (India)

Author keywords

12 lipoxygenase; 2 hydroxyeicosatetraenoic acid; Arachidonyl lipoxygenase 12; Breast cancer; Lipoxygenase; Polymorphism and gene variants; Single nucleotide polymorphism

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARGININE; GLUTAMINE;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 79551652304     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.209     Document Type: Article

References (63)

1. Honn KV, Tang DG, Gao X, Butovich, I.A, Liu B, Timar J and Hagmann W: 12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Res 13: 365-396, 2003.
2. Tang DG, Chen YQ and Honn KV: Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 93: 5241-5246, 1996.
3. Connolly JM and Rose DP: Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice. Cancer Lett 132: 107-112, 1998.
4. Kamitani H, Ikwa H, Hsi LC, Wantanabe T, Dubois RN and Eling TE: The possible involvement of 15-lipoxygenase/ leukocyte type 12-lipoxygenase in colorectal carcinogenesis. Adv Exp Med Biol 469: 593-598, 1999.
5. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman C and Kelloff GJ: Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8: 467-483, 1999.
6. Jatana M, Giri CC, Ansari MA, Elango C, Singh AK, Singh I and Khan I: Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation 11: 3-12, 2006.
7. Furstenberger G, Krieg P, Muller-Decker K and Habenicht AJ: What are cycloxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? int J Cancer 119: 2247-2254, 2006.
8. Tavolari S, Bonafe M, Marina MM, et al: A dual COX/5-LOX inhibitor induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29: 371-380, 2008.
9. Hersberger M: Potential role of the lipoxygenase-derived lipid mediators in atherosclerosis; leukotrienes, lipoxins and resolvins. Clin Chem Lab Med 48: 1063-1073, 2010.
10. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875, 2001.
11. Nie D and Honn KV: Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 59: 799-807, 2002.
12. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, Lee MJ and Yang CS: Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25: 1671-1679, 2004.
13. Matsuyama M and Yoshimura R: The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics: Targets and Therapy 2: 725-732.
14. Brash AR: Lipoxygenases: occurrence, functions, catalysis, and acquisitions of substrate. J Biol Chem 274: 23769-23682, 1999.
15. Yamamoto S, Suzuki H, Nakamura M and Ishimura K: Arachidonate 12-lipoxygenase isozymes. Adv Exp Med Biol 447: 37-44, 1999.
16. Shureiqi I and Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61: 6307-6312, 2001.
17. Phillis JW, Horrocks LA and Farooqui AA: Cyclooxygenases, lipoxygenases and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52: 201-243, 2006.
18. Prasad VVTS, Nithipatikom K and Harder DR: Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. Neurochem Int 53: 220-229, 2008.
19. Marks F and Furstenberg G: Eicosanoids and cancer. In: Prostaglandins, Leukotrienes and Other Eicosanoids: From Biogenesis to Clinical Applications. Marks F and Furstenberger G (eds). Wiley VCH, Weinheim, pp303-330, 1999.
20. Cuendet M and Pezzuto JM: The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17: 109-157, 2000.
21. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R and Das S: Arachidonic acid and colorectal carcinogenesis. Mol Cell Biochem 253: 141-149, 2003.
22. Dannenberg AJ and Subbaramaiah K: Targeting cyclooxygenase 2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436, 2003.
23. Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ and Lee VMY: 12/15-Lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 164: 1655-1662, 2004.
24. Yao Y, Clark CM, Trojanowski JQ, Lee VMY and Pratico D: Elevation of 12/15-lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58: 623-626, 2005.
25. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Levkovitz H and Sigal E: Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor - deficient mice. Arterioscl Thromb Vasc Biol 20: 2100-2105, 2000.
26. Takahashi Y, Zhu H and Yoshimoto T: Essential roles of lipoxygenases in LDL oxidation and development of atherosclerosis. Antioxid Redox Signal 7: 425-431, 2005.
27. Quintana LF, Guzman B, Collado S, Claria J and Poch E: A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE in hypertension. Kidney Int 69: 526-530, 2006.
28. Musiek ES, Breeding RS, Milne GL, Zanoni G, Marrow JD and McLaughlin B: Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J Neurochem 97: 1301-113, 2006.
29. Hao CM and Breyer MD: Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71: 1105-1115, 2007.
30. Howe LR and Dannenberg AJ: A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 29 (Suppl 11): 111-119, 2002.
31. Nie D, Krishnamoorthy S, Jin R, Tang K, Chen YC, Qiao Y, Zacharek A, Guo Y, Milanini J, Page G and Honn KV: Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 281: 18601-18609, 2006.
32. Chen FL, Wang XZ, Li JY, Yu P, Huang Y and Chen ZX: 12-Lipoxygenase induces apoptosis of human gastric cancer AGS cells via the ERK1/2 signal pathway. Dig Dis Sci 53: 181-187, 2008.
33. Bhattacharya S, Mathew W, Jayne DG, Plengaris S and Khan M: 15-Lipoxygenase-1 in colorectal cancer: a review. Tumor Biol 30: 185-199, 2009.
34. You J, Mi D, Zhou X, Qiao L, Zhang H, Zhang X and Ye L: A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology 150: 1607-1617, 2009.
35. Gao X, Grignon DJ, Chbhi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ and Honn KV: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46: 227-237, 1995.
36. Jiang WG, Douglas-Jones A and Mansel RE: Levels of expression in lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 69: 275-281, 2003.
37. Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Weel T and Eimen G: Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer 43: 163-168, 2009.
38. Krueger JS, Keshamouni VG, Atanaskova N and Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20: 4209-4218, 2001.
39. Zhou X, Lin Y, You J, Zhang X and Ye L: Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through crosstalk with activated ERK 1/2. Cancer Lett 270: 312-327, 2008.
40. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D and Lin D: Association of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 28: 1197-1201, 2007.
41. Miller S, Dykes D and Polesky H: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
42. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ and Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 25: 2467-2472, 2004.
43. Gong Z, Hebert JR, Bostick RM, Deng Z, Hurley TG, Dixon DA, Nitcheva D and Xie D: Common polymorphisms in 5-lipoxy-genase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma. Cancer 109: 849-857, 2007.
44. Kim T, Kim HJ, Park JK, Kim JW and Chung JH: Association between polymorphisms of arachidonate 12-lipoxygenase (ALOX12) and schizophrenia in a Korean population. Behav Brain Functions 6: 44, 2010.
45. Fridman C, Ojopi EP, Gregório SP Ikenaga EH, Moreno DH, Demetrio FN, Guimarães PE, Vallada HP, Gattaz WF and Dias Neto E: Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 253: 40-43, 2003.
46. Danaei G, Hoorn SV, Lopez AD, Murray CJ and Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioral and environmental risk factors. Lancet 366: 1784-1793, 2005.
47. American Cancer Society: Cancer Facts and Figures 2008. American Cancer Society, Atlanta, 2008.
48. Porter PL: Global trends in breast cancer incidence and mortality. Salud Public Mex (Suppl 2): 141-146, 2009.
49. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
50. Morrow KPH, Zambrana F and Esteva FJ: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast cancer Res 11: 209, 2009.
51. Lynch HT, Silva E, Snyder C and Lynch JF: Hereditary breast cancer: Part I. Diagnosing hereditary breast cancer syndromes. Breast J 14: 3-13, 2008.
52. Matsuyama M and Yoshimura R: The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics 294: 725-732, 2008.
53. Liu Y, Freedman BI, Kathryn P, Burdon KP, Langefeld CD, Howard T, Herrington D, Goff DC Jr, Bowden DW, Wagenknecht LE, Hedrick CC and Rich SS: Association of arachidonate 12-lipoxygenase genotype variation and glycemic control with albuminuria in type 2 diabetes. Am J Kidney Dis 52: 242-250, 2008.
54. Liu LP, Recker RR, Deng HW and Dvornyk V: ALOX12 gene is associated with the onset of natural menopause in white women. Menopause 17: 152-156, 2010.
55. Guo Y, Zhang X, Ta W, Miao X, Sun T, Zhao D and Lin D: Platelet 12-lipoxygenase Arg261Gln Polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics 17: 197-205, 2007.
56. Aleem AM, Jankun J, Dignam JD, Walther M, Kohn H, Svergun D and Skrzypczak-Jankun E: Human platelet 12-lipoxy-genase, new findings about its activity, membrane binding and resolution structure. J Mol Biol 376: 193-209, 2007.
57. Aleem AM, Wells L, Jankun J, Walther M, Kohn H, Reinartz J and Skrzypczak-Jankun E: Human platelet 12-lipoxygenase: naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior. Int J Mol Med 24: 759-764, 2009.
58. Pidgeon GP, Kandouz M, Meram A and Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 62: 2721-2727, 2002.
59. Flavin DFA: Lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 82: 91-93, 2007.
60. Nigam S, Zafiriou MP, Deva R, Ciccoli R and Roux-Van der Merwe R: Structure, biochemistry and biology of hepoxilins: an update. FEBS J 274: 3503-3512, 2007.
61. Pidgeon GP, Lysaght J, Krishanamoorthy S, Reynolds JV, O'Byrne K, Nie D and Honn KV: Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26: 503-524, 2007.
62. Choi CK, Sukhthankar M, Kim CH, Lee SH, English A, Kihm KD and Baek SJ: Cell adhesion property affected by cyclooxygenase and lipoxygenase: opto-electric approach. Biochem Biophys Res Commun 391: 1385-1389, 2010.
63. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA and Nadler JL: 12-Lipoxygenase products reduce insulin secretion and {beta}-cell viability in human islets. J Clin Endocrinol Metab 95: 887-892, 2010.